参考文献
(在框内滑动手指即可浏览)
[1] Wells SA,Asa SL,Dralle H,et al.Revised American Thyroid Association Guidelines for the management of medullary thyroid carcinoma[J].Thyroid,2015,25(6):567-610.
[2] Viola D,Elisei R. Management of medullary thyroid cancer[J].Endocrinol Metab Clin North Am,2019,48(1):285-301.
[3] Chen L,Qian K,Guo K,et al.A Novel n staging system for predicting survival in patients with medullary thyroid cancer[J].Ann Surg Oncol,2019,26(13):4430-4438.
[4] Zhang T,Qu N,Hu JQ,et al.Mediastinal lymph node metastases in thyroid cancer: characteristics, predictive factors, and prognosis[J].Int J Endocrinol,2017,2017:1868165..
[5] Machens A,Dralle H,Dralle H.Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening[J].Eur J Endocrinol,2016,175(3):219-228.
[6] Detterbeck FC,Boffa DJ,Kim AW,et al.The eighth edition lung cancer stage classification[J].Chest,2017,151(1):193-203.
[7] Liu J,Wang X,Liu S,et al.Superior mediastinal dissection for papillary thyroid carcinoma: approaches and outcomes[J].ORL J Otorhinolaryngol Relat Spec,2013,75(4):228-239.
[8] 张再兴,李正江,唐平章,等.甲状腺髓样癌的外科治疗及预后分析[J].中华耳鼻咽喉头颈外科杂志,2011,46(3):209-213.
[9] 鄢丹桂,张彬,李正江,等.甲状腺髓样癌颈部淋巴转移规律的临床研究[J].中华耳鼻咽喉头颈外科杂志,2015,50(4):290-294.
[10] Costante G,Meringolo D.Calcitonin as a biomarker of C cell disease: recent achievements and current challenges[J].Endocrine,2020,67(2):273-280.
[11] Machens A,Dralle H,Dralle H.Biomarker-based risk stratification for previously untreated medullary thyroid cancer[J].J Clin Endocrinol Metab,2010,95(6):2655-2663.
[12] 叶柳青,丁金旺,周国明,等.血清癌胚抗原预测可手术甲状腺髓样癌淋巴结转移的临床价值[J].中华内分泌外科杂志,2020,14(1):37-41.
[13] Brammen L,Niederle MB,Riss P,et al.Medullary thyroid carcinoma: do ultrasonography and F-DOPA-PET-CT influence the initial surgical strategy?[J].Ann Surg Oncol,2018,25(13):3919-3927.
[14] 张浩,张大林.甲状腺髓样癌诊治难点及对策[J].中国实用外科杂志,2019,39(3):225-230.
[15] Rodríguez-Bel L,Sabaté-Llobera A,Rossi-Seoane S,et al.Diagnostic accuracy of 18F-FDG PET/CT in patients with biochemical evidence of recurrent, residual, or metastatic medullary thyroid carcinoma[J].Clin Nucl Med,2019,44(3):194-200.
[16] Treglia G,Villani MF,Giordano A,et al.Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis[J].Endocrine,2012,42(3):535-545.
[17] Giovanella L,Treglia G,Iakovou I,et al.EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma[J].Eur J Nucl Med Mol Imaging,2020,47(1):61-77.
[18] Treglia G,Cocciolillo F,Di Nardo F,et al.Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis[J].Acad Radiol,2012,19(10):1290-1299.
[19] Romero-Lluch AR,Cuenca-Cuenca JI,Guerrero-Vázquez R,et al.Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff[J].Eur J Nucl Med Mol Imaging,2017,44(12):2004-2013.
[20] Archier A,Heimburger C,Guerin C,et al.(18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma[J].Eur J Nucl Med Mol Imaging,2016,43(6):1027-1033.
[21] Kushchayev SV,Kushchayeva YS,Tella SH,et al.Medullary thyroid carcinoma: An update on imaging[J].J Thyroid Res,2019,2019:1893047.
[22] Rowland KJ,Jin LX,Moley JF,et al.Biochemical cure after reoperations for medullary thyroid carcinoma: a meta-analysis[J].Ann Surg Oncol,2015,22(1):96-102.
[23] 王宇,渠宁,史潇,等.甲状腺髓样癌诊治现状及热点问题思考[J].肿瘤预防与治疗,2019,32(6):475-479.
[24] Ducic Y,Oxford L,Oxford L.Transcervical elective superior mediastinal dissection for thyroid carcinoma[J].Am J Otolaryngol,2009,30(4):221-224.
[25] 刘绍严,刘杰.甲状腺癌上纵隔淋巴结转移外科治疗策略[J].中国实用外科杂志,2017,37(9):959-961.
[26] 章德广,陈剑,何高飞,等.腔镜上纵隔淋巴结清扫术在甲状腺乳头状癌治疗中的运用[J].中国普通外科杂志,2018,27(12):1583-1588.